These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 37904221)
1. Efficacy and safety of baricitinib in treatment of systemic lupus erythematosus: a systematic review and meta-analysis. Allam AR; Alhateem MS; Mahmoud AM BMC Rheumatol; 2023 Oct; 7(1):40. PubMed ID: 37904221 [TBL] [Abstract][Full Text] [Related]
2. Treatment of active systemic lupus erythematosus with baricitinib: A meta-analysis of randomized controlled trials. Lee YH; Song GG Lupus; 2023 Nov; 32(13):1493-1500. PubMed ID: 37853751 [TBL] [Abstract][Full Text] [Related]
3. Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials. Amer BE; Afifi E; Mouffokes A; Hamad AA; Amin AM; Abdelwahab OA Clin Rheumatol; 2024 Feb; 43(2):579-589. PubMed ID: 37581759 [TBL] [Abstract][Full Text] [Related]
4. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. Loncharich MF; Anderson CW ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of baricitinib for the treatment of systemic lupus erythematosus patients: A meta-analysis of randomized controlled trials. Panda AK; Ranjan S; Sahu JK Int J Rheum Dis; 2024 Jan; 27(1):e14964. PubMed ID: 37950554 [TBL] [Abstract][Full Text] [Related]
6. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Morand EF; Vital EM; Petri M; van Vollenhoven R; Wallace DJ; Mosca M; Furie RA; Silk ME; Dickson CL; Meszaros G; Jia B; Crowe B; de la Torre I; Dörner T Lancet; 2023 Mar; 401(10381):1001-1010. PubMed ID: 36848918 [TBL] [Abstract][Full Text] [Related]
7. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Petri M; Bruce IN; Dörner T; Tanaka Y; Morand EF; Kalunian KC; Cardiel MH; Silk ME; Dickson CL; Meszaros G; Zhang L; Jia B; Zhao Y; McVeigh CJ; Mosca M Lancet; 2023 Mar; 401(10381):1011-1019. PubMed ID: 36848919 [TBL] [Abstract][Full Text] [Related]
8. Baricitinib in the treatment of systemic lupus erythematosus: a systematic review of randomized controlled trials. Shah HH; Ashfaque F; Hadi Z; Waseem R; Rauf SA; Hussain T; Anas Z; Zehra SA; Hussain MS; Wasay Zuberi MA; Haque MA Ann Med Surg (Lond); 2024 Aug; 86(8):4738-4744. PubMed ID: 39118746 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of baricitinib in the treatment of Systemic lupus erythematosus (SLE): A Systemic review and meta-analysis. Zaidi SMM; Ahmed Fatmi SA; Ashraf MH; Waheed F; Jawwad M; Hai AA; Ahmed SA Heliyon; 2023 Dec; 9(12):e22643. PubMed ID: 38076200 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis. Ma L; Peng L; Zhao J; Bai W; Jiang N; Zhang S; Wu C; Wang L; Xu D; Leng X; Wang Q; Zhang W; Zhao Y; Tian X; Li M; Zeng X Autoimmun Rev; 2023 Dec; 22(12):103440. PubMed ID: 37678618 [TBL] [Abstract][Full Text] [Related]
11. Interventions for cutaneous disease in systemic lupus erythematosus. Hannon CW; McCourt C; Lima HC; Chen S; Bennett C Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520 [TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
14. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749 [TBL] [Abstract][Full Text] [Related]
15. Belimumab for systemic lupus erythematosus. Singh JA; Shah NP; Mudano AS Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010668. PubMed ID: 33631841 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of baricitinib in patients with alopecia areata: a systematic review and Meta-analysis of randomized controlled trials. Mahmoud AM Curr Med Res Opin; 2023 Feb; 39(2):249-257. PubMed ID: 36239359 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety study of targeted small-molecule drugs in the treatment of systemic lupus erythematosus. Wang S; Ning W; Tang H; Mu C; Huang X Arthritis Res Ther; 2024 May; 26(1):98. PubMed ID: 38730460 [TBL] [Abstract][Full Text] [Related]